Based on the emerging neuroprotective roles of ApoD the aim of this pilot study was to evaluate (1) ApoD levels in a cohort of healthy controls to verify the effect of aging on ApoD as well as the levels of TNF-α in order to get a better insight of the increase in ApoD during the “inflamm-aging” process [2, 24], (2) differences in ApoD levels between PD and age-matched healthy controls, and (3) differences in ApoD levels according to different levels of neurological impairment. This evidence concerns the gene APOD and Parkinson disease.